Who is sponsoring NCT04131244?

NCT04131244 is sponsored by Hacettepe University.

What condition does NCT04131244 study?

NCT04131244 studies Activation of Primordial Follicles.

Is NCT04131244 still recruiting?

NCT04131244 is currently completed. Last updated 12 February 2020.

Last reviewed 2020-02-12 · How we verify

NCT04131244

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

In Vitro Follicle Activation in Patient With Premature Ovarian Failure Under 36 Years Old

Completed NA Last updated 12 February 2020

What this trial tests

NA trial testing In vitro activation of primordial follicles by PTEN inhibitor and AKT stimulator in Activation of Primordial Follicles in 10 participants. Completed in 15 December 2019.

Timeline

1 December 2017

Primary endpoint
15 October 2019

15 December 2019

Quick facts

Lead sponsor	Hacettepe University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	1 December 2017
Primary completion	15 October 2019
Estimated completion	15 December 2019
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

In vitro activation of primordial follicles by PTEN inhibitor and AKT stimulator

Conditions studied

Activation of Primordial Follicles — all drugs for Activation of Primordial Follicles →

Sponsor

Hacettepe University

Who can join

Adults 18 to 36, female only, with Activation of Primordial Follicles. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a clinical trial that the investigators aim to validate In-vitro Activation (IVA) treatment protocol, which was previously defined by Kazuhiro Kawamura (MD) and Aaron Hsueh (PhD), in Turkish patient with Premature Ovarian Insufficiency (POI) under age 36.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

PTEN inhibitor bpV(HOpic) confers protection against ionizing radiation.
Chauhan A, Sah DK, Kumari N, Kalra N, et al · · 2021 · cited 10× · PMID 33462262 · DOI 10.1038/s41598-020-80754-8

Verify or expand the search:

Other Hacettepe University trials

Trials by the same sponsor.

NCT07522060 — Early Functional Response as a Predictor of Clinical Outcomes in Hand Rehabilitation: A Prospective Feasibility Study Us · not yet recruiting
NCT07390162 — The Effect of Changes in the Frequency of Endotracheal Tube Repositioning in Intensive Care Units on the Prevention of O · NA · not yet recruiting
NCT07579676 — DEVELOPMENT AND PSYCHOMETRIC EVALUATION OF THE NEUROCOGNITIVE UPPER EXTREMITY TESTS: A RELIABILITY AND VALIDITY STUDY · not yet recruiting
NCT07524842 — Clinical Performance of Three Different Restorative Materials · NA · not yet recruiting
NCT07439861 — The Effect of Cognitive Dual-Task on Athletic Performance Parameters in Volleyball Players With and Without Chronic Ankl · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04131244 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hacettepe University
Last refreshed: 12 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04131244.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing